Biotech Co.* (Country; Symbol) Pharma Co. (Country) Type/Product Area Terms/Details (Date)
Addex Pharmaceuticals (Switzerland; SWX:ADXN) Merck & Co. Inc. Agreement to develop ADX63365 for schizophrenia The deal is potentially worth $702M; Merck will pay Addex $22M up front and up to $455M in research, development, regulatory and sales milestones if a product is marketed for schizophrenia and a second undisclosed indication (1/3)
Alfacell Corp. (ACEL) Strativa Pharmaceuticals Licensing agreement for U.S. commercialization rights for the Phase III cancer drug Onconase The deal is worth $225M, with $5M up front, $30M for FDA approval in unresectable malignant mesothelioma, and up to $190M for milestones tied to Onconase sales as well as development and commercialization of the drug in additional indications (1/15)
Amgen Inc. (AMGN) Takeda Pharmaceutical Co. Ltd. (Japan) Agreement for Takeda to take over Japanese rights to 13 molecules, including Vectibix Amgen will receive $200M up front, and could bank $362M more in milestone payments; Takeda also will pay up to $340M in worldwide development costs for molecules to treat cancer, inflammation and pain; in addition, Amgen is entitled to royalties (2/4)
Amira Pharmaceuticals Inc.* GlaxoSmithKline plc (UK) Licensing agreement for AM103 and the rest of Amira's 5-lipoxygenase activating protein inhibitor program for respiratory and cardiovascular disease The deal could bring Amira $425M in up-front fees and development milestone payments, as well as tiered royalties and additional milestone payments tied to sales (2/4)
ApoCell Inc.* Pfizer Inc. Agreement for ApoCell to use its target expression profile technology and immunohisto-chemistry expertise to analyze biomarkers in a Phase I trial Terms were not disclosed (1/25)
BioMS Medical Corp. (Canada; TSX:MS) Eli Lilly and Co. Licensing and development agreement for exclusive, worldwide rights to BioMS's MBP8298 to treat multiple sclerosis Financial terms were not disclosed (1/28)
BioSeek Inc.* Dainippon Sumi-tomo Pharma Co. (Japan) Partnership to develop drug candidates to treat inflammation and metabolic disorders BioSeek will apply its BioMAP systems to support compound differentiation, lead development and drug candidate selection activities for DSP's discovery programs in inflammation and metabolic diseases (1/24)
Cellartis* (Sweden) Pfizer Inc. Research collaboration for the development of a novel model system for detecting human toxicity in vitro The goal is to generate a predictive developmental screening model for new chemical entities using the Cellartis human embryonic stem cell platform (2/13)
Compugen Ltd. (Israel; CGEN) Merck and Co. Inc. Agreement to discover peptides that activate selected G protein-coupled receptors Financial terms were not disclosed (1/14)
Compugen Ltd. (Israel; CGEN) Roche AG (Switzerland) Collaboration covering the identification and validation of genetic variations for the prediction of response to drugs used for the treatment of rheumatoid arthritis Compugen will analyze DNA samples and clinical data provided by Roche to identify and validate nonsingle nucleotide poly-morphism genetic variations that could serve as biomarkers for the predicted response or nonresponse to selected drugs (12/20)
Crucell NV (the Netherlands; CRXL) Sanofi Pasteur (France) Exclusive agreement for Crucell's rabies monoclonal antibodies as next-generation rabies biologicals to be used in conjunction with Sanofi's rabies vaccine to prevent viral infection in people exposed to rabies Crucell will receive €10M up front and could get milestones of up to €66.5M down the road; the firm also will be entitled to an undisclosed royalty percentage on sales of the final product by Sanofi (1/3)
Curis Inc. (CRIS) Stryker Corp. Licensing agreement for Curis' bone morphogenetic protein-7 program Stryker gains the rights in exchange for $1M up front and undisclosed clinical, regulatory and sales milestones; Curis said global commercialization of a BMP-7 product could result in $41M in payments (12/28)
Dyax Corp. (DYAX) Sanof-Aventis Partnership giving Sanofi rights to develop and commercialize DX-2240, a pre-clinical cancer compound, plus nonexclusive rights to use Dyax's antibody phage display technology to discover and develop additional compounds Dyax expects to receive at least $25M this year, and could receive up to $500M in total up-front and milestone payments upon commercial success of the first five antibody programs (2/12)
Faust Pharmaceuticals SA* (France) Takeda Pharmaceutical Co. Ltd. (Japan) Research agreement in which Faust will apply its Neuroclid platform to identify novel drug candidates that target undisclosed G protein-coupled receptors of interest to Takeda Financial terms were not disclosed (1/7)
Flamel Technologies (France; FLML) Merck Serono Collaboration to investigate the applicability of Flamel's Medusa technology for the extended release of a therapeutic protein of Merck Serono's portfolio Merck Serono will make an up-front payment of €2M ($2.86M) to Flamel, and it will fund R&D efforts to be performed at Flamel (12/20)
Galapagos NV (Belgium; BR: GLPG) Janssen Pharmaceutica (unit of Johnson & Johnson) Two-year target discovery collaboration in the field of oncology BioFocus DPI, Galapagos' service division, will apply Galapagos' adenoviral platform to identify novel drug targets for development; BioFocus DPI will receive an up-front payment of $4.3M; it also may receive research, acceptance, license and development fees of up to €7.6M for milestones achieved (1/3)
Gastrotech Pharma* (Denmark) Eli Lilly and Co. Agreement to in-license the Lilly compound now named GTP-010, an analogue of the naturally occurring intestinal hormone GLP-1 Gastrotech will receive a global exclusive license to develop and market GTP-010 for irritable bowel syndrome and functional dyspepsia; Lilly will take an equity stake in Gastrotech and will receive royalties on sales (1/28)
Genomic Health Inc. (GHDX) Pfizer Inc. Collaboration for development of a genomic test to estimate the risk of recurrence following surgery for patients with Stage I-III renal carcinoma, clear cell type, that has not spread to other parts of the body Financial terms were not disclosed (1/7)
Helix BioMedixInc. (OTC BB:HXBM) Peptisyntha Inc. (an affiliate of Solvay SA; Belgium) Manufacturing and supply agreement for certain peptides Peptisyntha will supply Helix with the peptides for two years (1/18)
Hologic Inc. (HOLX) KV Pharmaceutical Co. Licensing agreement for Gestiva (17-alpha hydroxy-progesterone) KV Pharma agreed to pay diagnostics company Hologic $82M in cash for world-wide rights to the drug, with $7.5M due at closing and the remaining $74.5M due upon FDA approval and production of launch quantities of the drug (1/22)
LifeCycle Pharma A/S (Denmark; CSE:LCP) Undisclosed pharma firm Collaboration agreement for the pharma firm to use its MeltDose technology to conduct a preclinical feasibility study of a new formulation of one of its product candidates Financial terms were not disclosed (12/20)
Meditrina Pharmaceuticals Inc.* AstraZeneca Inc. (UK) Global licensing agreement to develop and market aromatase inhibitors in combination with the hormones estrogen and progestin to treat endometriosis Financial terms were not disclosed (2/6)
Nektar Therapeutics (NKTR) Baxter International Agreement to develop new pegylated therapies to treat hemophilia Nektar will receive up to $44M in up-front and milestone payments, funding of research and development, and manufacturing revenues during research, clinical development and commercialization; Nektar also will receive royalties (12/20)
Novexel SA* (France) Forest Laboratories Holdings Ltd. (subsidiary of Forest Laboratories Inc.) Agreement allowing Forest to develop, manufacture and commercialize Novexel's intravenous beta lactamase inhibitor, NXL104, in combination with Forest's ceftaroline Forest will pay Novexel an up-front license fee of €75M ($109.6M) and fund the development and commercialization of the ceftaroline/NXL104 combination; Novexel could be eligible for additional milestone payments of up to €75M if the combination product is developed successfully; the deal also includes double-digit royalties to Novexel on sales throughout North America (1/22)
Paion AG (Germany; BE:PA8) H. Lundbeck A/S (Denmark) Agreement under which Lundbeck will take on all future development and global commercialization responsibility for the compound Paion is to receive an up-front payment of $11.7M and could receive a total of €38M €25M in development-based and sales-based milestones, as well as double-digit royalties (12/31)
PsychoGenics Inc.* Eli Lilly and Co. Drug discovery agreement for Lilly to supply pre-candidate compounds that PsychoGenics will evaluate for the treatment of neuro-psychiatric disorders If Lilly develops clinical candidates, Psycho-Genics would receive research and milestone payments, and royalties (1/31)
Rosetta Genomics (subsidiary of Rosetta Genomics Inc.; ROSG) Roche Molecular Systems License agreement for Rosetta to use Roche's PCR technology in its microRNA-based diagnostic tests Further terms were not disclosed (1/7)
Scil Technology GmbH* (Germany) Pfizer Inc. Agreement for rights to cartilage-derived retinoic acid sensitive protein The deal is worth as much as $250M in up-front and milestone payments from Pfizer; Scil also would receive royalties (1/16)
Sepracor Inc. (SEPR) Nycomed (Switzerland) Agreement for Sepracor to acquire the U.S. development, marketing and commercialization rights to Nycomed's ciclesonide-based products The deal is worth $430M; Sepracor will pay Nycomed an up-front payment of $150M and subsequent payments of up to $280M if certain develpment and sales milestones are met; Nycomed also is eligible to receive compensation for providing finished products and royalties on an undisclosed amount on sales of ciclesonide-based products (1/29)
Source MDx Inc.* Pfizer Inc. Multiyear collaboration to develop RNA-based biomarkers for Pfizer's cancer and inflammatory disease pipelines The goal is to create companion diagnostics to be marketed in tandem with targeted drugs (12/27)
Tacere Therapeutics Inc.* Pfizer Inc. Agreement to develop and commercialize TT-033, a preclinical hepatitis C drug consisting of three short-hairpin RNAs delivered within an adeno-associated virus protein coat Tacere will receive an undisclosed up-front payment as well as up to $145M in milestone payments from Pfizer (1/7)
TransTech Pharma Inc.* (Denmark) Novo Nordisk A/S (Denmark) Agreement under which TransTech acquired all rights from Novo Nordisk to a portfolio of drug candidates, including H3 receptor antagonists, PPARd agonists, and 11-beta HSD1 inhibitors, being developed to treat metabolic disorders Further details were not disclosed (1/25)
Notes:

# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk. ** Denotes the date the item ran in BioWorld International.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

BR = Brussels Stock Exchange; CSE = Copenhagen Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SWX = Swiss Stock Exchange; TSX = Toronto Stock Exchange.